Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
As scientists move closer to testing regenerative therapies for eye disease, techniques are needed to monitor transplanted cells as they integrate with host tissues.
In a pair of papers on retinal structure, Duke University neurobiologists have shown that the rigors of natural selection and evolution have shaped the retinas in our eyes just as this theory of optimization would predict.
Neural circuits in the primate retina can generate the information needed to predict the path of a moving object before visual signals even leave the eye, UW Medicine researchers demonstrate in a new paper.
New biomarkers found in the eyes could unlock the key to helping manage diabetic retinopathy, and perhaps even diabetes, according to new research conducted at the Indiana University School of Optometry.
A National Eye Institute-funded project at Duke University has yielded a fully automated optical coherence tomography (OCT) device that does not require a trained operator and promises to broaden access to retinal imaging technology.
Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye.
A new combination of optical coherence tomography (OCT), adaptive optics and deep neural networks should enable better diagnosis and monitoring for neuron-damaging eye and brain diseases like glaucoma.
As regenerative therapies for blinding diseases move closer to clinical trials, the NEI's functional imaging consortium is pioneering noninvasive technologies to monitor the function of the retina’s neurons and their connections to the brain.
Researchers at the University of Wisconsin have developed a micro-molded scaffolding photoreceptor “patch” designed to be implanted under a damaged or diseased retina.
LambdaVision, the Farmington, Connecticut-based biotech firm that developed the artificial retina, is exploring optimizing production of an artificial retina in space, in a series of missions to the International Space Station.
